Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

MOTS-c + Humanin Stack

Mitochondrial Peptide Stack · MDP Stack · MOTS-c/Humanin

Animal replicated

Research chemicalMitochondrial Peptide Peptide Stack Metabolic Signaling

RouteInjectableGray-market only

Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance

What it is: MOTS-c + Humanin — Mitochondrial-Derived Peptide Stack — Mitochondrial Peptide, Peptide Stack, Metabolic Signaling.
Why people use it: Used primarily for mitochondrial health and longevity and anti-aging.
What the evidence supports: No controlled human trial has tested the MOTS-c + Humanin combination. Human evidence is component-level only: MOTS-c has limited human metabolic/biomarker data and Humanin has observational/correlative aging data, but the stack itself has zero stack-specific human RCTs.

If you only read one thing

MOTS-c and Humanin represent a genuinely new category of biology — the mitochondrial genome encoding systemic regulatory signals beyond energy production. The pharmacological case for their combination is clean: MOTS-c targets metabolic regulation (AMPK, folate/methionine cycle, glucose uptake, exercise response); Humanin targets cellular survival (anti-apoptotic, neuroprotective, anti-inflammatory). These are non-overlapping mechanisms addressing complementary hallmarks of aging. Both decline with age. Both have animal evidence for the benefits they are claimed to produce. Both have essentially no human RCT evidence for their use as injectable peptides in community protocols. The stack sits at the intersection of genuinely interesting biology and essentially unvalidated community application.

Check interactions →

Route / form

Same compound, route-specific context. Switch forms instead of opening separate pages.

Evidence fit

Route-specific

Use the route notes below to match form, goal, and evidence quality.

Route caveat

Protocol not standardized

No route-matched protocol rows were parsed for this form; use the route notes and full dosing chapter before comparing options.

Protocol anchor

Full dosing section

Open the full report at the dosing chapter for protocol rows, cycle context, and administration notes.

Typical dose snapshot

See route notes

Evidence varies by use case

Evidence reality check

Evidence snapshot

No controlled human trial has tested the MOTS-c + Humanin combination. Human evidence is component-level only: MOTS-c has limited human metabolic/biomarker data and Humanin has observational/correlative aging data, but the stack itself has zero stack-specific human RCTs.

From the chapter quick-reference block.

Risk posture

No major flags listed

Review route-specific cautions before use.

Categories

Mitochondrial & Energy Longevity & Anti-aging Cognition & Mood Weight Loss & Metabolic

Properties

Not injectable

Evidence

CAnimal replicated

Stack Identity

Type: stack. Slug: motsc-humanin-stack. stackGrade: C. Components: mots-c + humanin. Both are mitochondria-derived peptides (MDPs) — the first class of signaling peptides encoded by mitochondrial DNA small open reading frames (smORFs). Limitless sells this specific combination. relatedStacks: none defined; related individual chapters: pbmotscv4, pbhumaninv4.

The Mitochondrial Peptide Class

MOTS-c and Humanin are both mitochondrial-derived peptides (MDPs). MDPs are a newly recognized class of bioactive peptides encoded by small open reading frames (smORFs) in the mitochondrial genome — DNA that was previously thought to encode only 13 proteins, 22 tRNAs, and 2 rRNAs. The discovery that mitochondrial DNA also encodes signaling peptides with systemic physiological effects was made in the 2000s-2010s. Both peptides are endogenous, circulate in blood, and decline with age. Both are believed to mediate some of the benefits of metabolic health and exercise.

MOTS-c (Mitochondrial ORF of the 12S rRNA type-c)

21-amino acid peptide encoded by the 12S rRNA region of mitochondrial DNA. Discovered by Lee et al. (2015, Cell Metabolism). Primary mechanism: AMPK activation via folate cycle and methionine cycle regulation. Acts as an exercise mimetic — injected MOTS-c in sedentary mice produces metabolic improvements similar to those seen with exercise. Age-decline pattern: plasma levels significantly reduced in older vs younger humans. SubQ injection; 5-10 mg doses in community protocols.

Humanin (HN)

21-amino acid peptide encoded by the 16S rRNA region of mitochondrial DNA. Discovered by Hashimoto et al. (2001, Science). Primary mechanisms: anti-apoptotic (JAK2/STAT3 signaling); neuroprotection (blocks amyloid-beta toxicity in neuronal cell death assays); anti-inflammatory; IGF-1 binding protein modulation (IGFBP3 displacement). Plasma levels decline significantly with age — one study found 50% decline per decade after age 40. Intranasal or SubQ; mcg-range doses in community.

stackGrade C

Zero combination studies exist for MOTS-c + Humanin. The combination is pharmacologically coherent: non-overlapping mechanisms (metabolic/AMPK vs cytoprotective/anti-apoptotic) targeting complementary aging hallmarks. The individual components have Grade C (animal) and limited human observational evidence. The combination grade is C — assigned from individual component evidence because no combination evidence exists.

Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this class Compare 4 side by side →

SHLP2

Shared goal · cognition

The Metabolically Active Member of a Six-Peptide Family From the Same Mitochondrial Gene as Humanin. A Receptor Has Been Found. An Obesity Protection Mechanism Has Been Identified. Lower Levels Are Associated With Prostate Cancer Risk. No Human Trial Has Been Run.

CIT Stack

Same class · Peptide Stack

GH stack plus tesamorelin: a community combination built from GH-axis peptides with different regulatory identities, not a single FDA-approved product.

Humanin